相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial
Duk-Woo Park et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Anaemia, microcytosis and sirolimus-is iron the missing link?
Sofia Sofroniadou et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial
Robert Applegate et al.
EuroIntervention (2010)
The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential
Hiroyuki Mori et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome
David T. Teachey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Hepcidin-A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease
Joshua Zaritsky et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients
S. Demirjian et al.
CLINICAL TRANSPLANTATION (2009)
Posttransplant anemia: the role of sirolimus
Steven Fishbane et al.
KIDNEY INTERNATIONAL (2009)
Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease
Andreas L. Serra et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
A Novel Immunological Assay for Hepcidin Quantification in Human Serum
Vasiliki Koliaraki et al.
PLOS ONE (2009)
Obesity Increases Vascular Senescence and Susceptibility to Ischemic Injury Through Chronic Activation of Akt and mTOR
Chao-Yung Wang et al.
SCIENCE SIGNALING (2009)
Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS
Hongyan Li et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2009)
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2008)
Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
G. A. W. Bruyn et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry
Uwe Kobold et al.
CLINICAL CHEMISTRY (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
John J. Bissler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Reduction in erythropoietin resistance after conversion from Sirolimus to enteric coated mycophenolate sodium
Joshua J. Augustine et al.
TRANSPLANTATION (2008)
Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: Preliminary results
M. Masetti et al.
TRANSPLANTATION PROCEEDINGS (2008)
A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin
Sovan Sarkar et al.
HUMAN MOLECULAR GENETICS (2008)
Reduced exposure to calcineurin inhibitors in renal transplantation
Henrik Ekberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients
A. Sanchez Fructuoso et al.
TRANSPLANTATION PROCEEDINGS (2007)
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function
Peter Friend et al.
TRANSPLANT INTERNATIONAL (2007)
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Laura R. Pearce et al.
BIOCHEMICAL JOURNAL (2007)
Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry
Anthony T. Murphy et al.
BLOOD (2007)
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
Daniel T. Milton et al.
CANCER (2007)
Late introduction of sirolimus induces anemia in renal transplant recipients
Olivier Thaunat et al.
TRANSPLANTATION (2007)
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects
Christian Toso et al.
TRANSPLANTATION (2007)
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Yasemin Sancak et al.
MOLECULAR CELL (2007)
Molecular control of iron transport
Tomas Ganz
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Everolimus is a potent inducer of erythroid differentiation and gamma-globin gene expression in human erythroid cells
Cristina Zuccato et al.
ACTA HAEMATOLOGICA (2007)
Suppression of hepcidin during anemia requires erythropoietic activity
Mihwa Pak et al.
BLOOD (2006)
Effects of rapamycin on accumulation of α-, β- and γ-globin mRNAs in erythroid precursor cells from β-thalassaemia patients
Eitan Fibach et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Sirolimus interferes with iron homeostasis in renal transplant recipients
Annamaria Maiorano et al.
TRANSPLANTATION (2006)
Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase
J. Avruch et al.
ONCOGENE (2006)
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2006)
Anemia after renal transplantation
Behdad Afzali et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus
David Fernandez et al.
ARTHRITIS AND RHEUMATISM (2006)
Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System
Naohisa Tomosugi et al.
BLOOD (2006)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease
Igor Theurl et al.
BLOOD (2006)
Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials
Angela C. Webster et al.
TRANSPLANTATION (2006)
Posttransplantation anemia in adult renal allograft recipients: Prevalence and predictors
N Shah et al.
TRANSPLANTATION (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus
TS Larson et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
Josep M. Campistol et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
DA Reardon et al.
CLINICAL CANCER RESEARCH (2006)
Iron imports. IV. Hepcidin and regulation of body iron metabolism
T Ganz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Marked erythrocyte microcytosis under primary immunosuppression with sirolimus
MJ Kim et al.
TRANSPLANT INTERNATIONAL (2006)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
S6 kinase 2 potentiates interleukin-3-driven cell proliferation
R Cruz et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state
O Thaunat et al.
TRANSPLANTATION (2005)
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients
S Vítko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy
RGB Bonegio et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis:: Analysis of the underlying mechanisms
E Biecker et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Rapamycin ameliorates experimental autoimmune myocarditis
K Maeda et al.
INTERNATIONAL HEART JOURNAL (2005)
Rapamycin successfully treats post-transplant autoimmune hepatitis
N Kerkar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors
J Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus
J Villanueva et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2005)
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
G Stallone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models
L Lee et al.
GENES CHROMOSOMES & CANCER (2005)
Efficacy of rapamycin in patient with juvenile rheumatoid arthritis
B Foroncewicz et al.
TRANSPLANT INTERNATIONAL (2005)
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
A Donovan et al.
CELL METABOLISM (2005)
Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia
H Kulaksiz et al.
GUT (2004)
Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure
J Groetzner et al.
TRANSPLANTATION (2004)
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
SH Um et al.
NATURE (2004)
Long-term outcome of sirolimus rescue in kidney-pancreas transplantation
J Rogers et al.
TRANSPLANTATION (2004)
Rapamycin-mediated induction of γ-globin mRNA accumulation in human erythroid cells
C Mischiati et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
E Nemeth et al.
SCIENCE (2004)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Recovery of chronic renal impairment with sirolimus after lung transplantation
F Venuta et al.
ANNALS OF THORACIC SURGERY (2004)
Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients
JJ Augustine et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Prohepcidin accumulates in renal insufficiency
YEC Taes et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2004)
Targeting the molecular target of rapamycin (mTOR)
EK Rowinsky
CURRENT OPINION IN ONCOLOGY (2004)
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery
JW Moses et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines:: An approach to suppress R5 strains of HIV-1
A Heredia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
T Ganz
BLOOD (2003)
Prevalence and management of anemia in renal transplant recipients: A European survey
Y Vanrenterghem et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation
D Bouscary et al.
BLOOD (2003)
Ten years of sirolimus therapy in orthotopic liver transplant recipients
GW Neff et al.
TRANSPLANTATION PROCEEDINGS (2003)
Rapamycin attenuates load-induced cardiac hypertrophy in mice
T Shioi et al.
CIRCULATION (2003)
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
E Nemeth et al.
BLOOD (2003)
Early experience with sirolimus in lung transplant recipients with chronic allograft rejection
BC Cahill et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2003)
TOR signalling in bugs, brain and brawn
E Jacinto et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim et al.
CELL (2002)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
M Morice et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats
NR Simler et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
AI Benito et al.
TRANSPLANTATION (2001)
Orthotopic liver transplantation using low-dose tacrolimus and sirolimus
VC McAlister et al.
LIVER TRANSPLANTATION (2001)
Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice
G Nicolas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Liver transplantation using sirolimus and minimal corticosteroids (3-day taper)
JF Trotter et al.
LIVER TRANSPLANTATION (2001)
Regulation of translation initiation by FRAP/mTOR
AC Gingras et al.
GENES & DEVELOPMENT (2001)
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
CH Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload
C Pigeon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
AS MacDonald
TRANSPLANTATION (2001)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo et al.
ONCOGENE (2000)
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
BD Kahan
LANCET (2000)
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
JC Hong et al.
TRANSPLANTATION (2000)
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
H Kreis et al.
TRANSPLANTATION (2000)
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo:: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
M Majewski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
